Pharvaris (NASDAQ:PHVS) Rating Reiterated by Morgan Stanley

Morgan Stanley reaffirmed their overweight rating on shares of Pharvaris (NASDAQ:PHVS - Free Report) in a research report report published on Monday, Benzinga reports. Morgan Stanley currently has a $34.00 price objective on the stock.

A number of other research firms have also commented on PHVS. Wedbush reissued an outperform rating and issued a $35.00 price target on shares of Pharvaris in a research report on Thursday, April 11th. JMP Securities upped their price target on Pharvaris from $49.00 to $50.00 and gave the stock a market outperform rating in a report on Thursday, April 11th.

Pharvaris Stock Up 8.9 %

Shares of PHVS traded up $1.71 during trading hours on Monday, reaching $20.87. The company's stock had a trading volume of 50,600 shares, compared to its average volume of 103,518. The firm has a market cap of $664.50 million, a price-to-earnings ratio of -7.27 and a beta of -3.12. The company has a 50 day moving average of $24.01 and a two-hundred day moving average of $23.32. Pharvaris has a 1-year low of $7.93 and a 1-year high of $33.00.

Institutional Trading of Pharvaris

A number of large investors have recently bought and sold shares of PHVS. Hudson Bay Capital Management LP acquired a new stake in shares of Pharvaris during the third quarter worth approximately $812,000. Walleye Capital LLC boosted its position in shares of Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company's stock worth $1,691,000 after purchasing an additional 10,691 shares in the last quarter. Blackstone Inc. acquired a new position in shares of Pharvaris in the 4th quarter valued at $2,805,000. Vivo Capital LLC acquired a new stake in Pharvaris during the 4th quarter worth $7,994,000. Finally, Commodore Capital LP bought a new position in Pharvaris during the fourth quarter worth about $22,440,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).